Okyo Pharma announces plans to accelerate development of urcosimod

OKYO Pharma (OKYO) announces plans to accelerate the clinical development of urcosimod to treat Neuropathic Corneal Pain, NCP, through the analysis of its data following the early closure of its Phase 2 trial. The Phase 2 trial of urcosimod to treat NCP was being conducted at a single trial site at Tufts Medical Center in Boston, MA. The decision to close the trial now, with 17 patients having presently completed the study, is due to OKYO’s strong desire to access the currently masked data and use it to plan its expanded development program. The patients participating in the trial have all been diagnosed with long term chronic neuropathic corneal pain and had previously been treated with multiple therapies with very limited or no response. Significant interest has been seen in the trial from long-term sufferers of NCP, and OKYO believes it should expand the development program and move forward with a multicenter trial. A considerable number of potential patients have expressed an interest in participating in a future registrational trial.